Baloxavir inhibits the endonuclease activity of the polymerase acidic protein resulting in inhibition of influenza virus replication.
Early neuraminidase inhibitor therapy may result in better outcomes in patients hospitalized with influenza B-related pneumonia.
Results of early research support further development of a synthetic universal influenza vaccine.
Despite the higher effectiveness of the quadrivalent inactivated influenza vaccine against the added B virus lineage, trivalent inactivated influenza vaccine.
Compared with patients prescribed only an antiviral, patients who are prescribed both an antiviral and antibiotic have a lower risk for 3-day respiratory hospitalization.
The FDA has approved Fluad Quadrivalent (influenza vaccine, adjuvanted; Seqirus) for active immunization in patients 65 years of age and older against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine.
A double-dose of inactivated influenza vaccine may not increase the immunogenicity of the vaccine among pregnant women with HIV.
The FDA has approved the influenza A H5N1 vaccine for active immunization in patients 6 months of age and older with increased risk of exposure.